150
Participants
Start Date
July 24, 2023
Primary Completion Date
January 31, 2028
Study Completion Date
January 31, 2028
Placebo
The placebo is a solution matching the study vaccine formulation.
ACI-7104.056 at Dose A
The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
ACI-7104.056 at Dose B (optional)
The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
ACI-7104.056 at Dose C (optional)
The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
ACTIVE_NOT_RECRUITING
Katholisches Klinikum Bochum GmbH, Bochum
NOT_YET_RECRUITING
Paracelsus-Kliniken Deutschland GmbH & Co. KGaA, Kassel
RECRUITING
University Medical Centre Schleswig-Holstein, Kiel
RECRUITING
Hospital De La Santa Creu I Sant Pau, Barcelona
RECRUITING
Hospital Universitari Vall D Hebron, Barcelona
RECRUITING
Policlinica Gipuzkoa, Donostia / San Sebastian
RECRUITING
Hospital Universitario De La Princesa, Madrid
RECRUITING
Hospital Universitario Puerta De Hierro De Majadahonda, Majadahonda
RECRUITING
Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón
RECRUITING
King's College Hospital NHS Foundation Trust, London
RECRUITING
Re:Cognition Health Limited, London
RECRUITING
Northern Care Alliance NHS Foundation Trust, Salford
Lead Sponsor
Collaborators (1)
ICON Clinical Research
INDUSTRY
AC Immune SA
INDUSTRY